2013 EY Beyond Borders Report for the Life Science Industry

The business climate for the biotechnology industry remains challenging. In today’s “new normal,” venture capitalists are more selective, IPOs more elusive and alliance partners more demanding. And even as biotech companies grapple with these challenges, health care systems are undergoing a fundamental shift toward outcomes and pay-for-performance.

How is the industry dealing with the twin challenges of boosting operating efficiency and demonstrating economic value?

Are “HOLNets” gaining traction and making R&D more efficient?

What are companies doing differently to collect data and demonstrate the economic value of their products?

Ernst & Young’s Beyond Borders offers insights on these questions and more.

Want to learn more? 

Contact Phil Howard and the E&Y Life Sciences Team

in Phoenix at (602) 322-3000.



Posted in AZBio News, BioScience.